

Evaluation of *NUF2* and *GMNN* Expression in Prostate Cancer: Potential Biomarkers for Prostate Cancer Screening

Shaghayegh Pezeshki¹, Payam Hashemi², Alireza Salimi³, Sheida Ebrahimi⁴, Mandana Javan zad⁵, Amir Monfaredan*⁶

Abstract

Background: Prostate cancer (PC) is one of the most abundant cancers among men, and In Iran, has been responsible for 6% of all deaths from cancer in men. *NUF2* and *GMNN* genes are considered as loci of susceptibility to tumorigenesis in humans. Alterations in expression of these genes have been reported in various malignancies. The aim of our study was to test whether different *NUF2* and *GMNN* expression levels are associated with PC incidence and hence, might be considered as new molecular tools for PC screening.

Methods: Biopsy samples from 40 PC patients and 41 healthy Iranian men were used to determine the relative gene expression. After RNA extraction and cDNA synthesis, samples were analyzed using TaqMan Quantitative Real time PCR. Patients' background information, included smoking habits and family histories of PC, were recorded. Stages and grades of their PC were classified by the TNM tumor, node, metastasis (TMN) staging system based on standard guidelines.

Results: *NUF2* expression did not significantly differ between the groups, while *GMNN* expression was significantly greater in the PC specimens than in the controls.

Conclusions: Regarding the significant role of *GMNN* in various tumor phenotypes, and its importance in PC progression, the alteration in *GMNN* expression in PC samples vs. controls indicate that the genetic profiling of this cancer might be considered to personalize therapy for each patient in the future.

Keywords: Family history, Geminin (*GMNN*), Tumor staging, *NUF2*, Prostate cancer.

Introduction

Cancer is a leading cause of death worldwide, and expected to increase rapidly as populations grow (1, 2). In 2018, there were an estimated 18.1 million new cancer cases (17.0 million except for nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million except for nonmelanoma skin cancer). Prostate cancer (PC) is the second most frequent malignancy after lung cancer in men worldwide, accounting

for 1,276,106 new cases and 358,989 deaths (3.8% of all deaths caused by cancer in men) (3). The PC incidence rate varies greatly in different parts of the world; the highest rate was observed in North America, and the lowest in South Asia. The incident rate correlates strongly with increasing age, with the average age at the time of diagnosis being 66 years (4). The PC incidence was less in Iran than in the other parts

1: Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

2: School of Medicine, Tehran University of Medical Science, Tehran, Iran.

3: Department of Molecular and Cellular Sciences, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

4: Department of Genetic, Faculty of biology, Yazd University, Yazd, Iran

5: Medical Branch, Islamic Azad University, Tehran, Iran.

6: Department of Hematology, Faculty of Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran.

*Corresponding author: Amir Monfaredan; Tel: +989120715914; E-mail: amir.monfaredan@yahoo.com.

Received: 30 Sep, 2020; Accepted: 13 Oct, 2020

of the world, with an age-standardized rate (ASR) of 9.11/100,000 (5).

The key factor to reduce the PC mortality rate is early detection and improvement in therapeutic strategies. In many cases the late stages of the cancer are resistant to routine treatments (6); therefore, early detection, and more importantly prediction, are of great interest. Prostate cancer is highly correlated with various risk factors including age, family history, environmental exposures (7), and genetic and epigenetic alterations (8). Despite efforts to develop multiple risk measurement systems for diagnosis at the earliest cancer stages, all failed in PC prediction (9). Long-term survival is high in localized PC; however, metastatic PC remains largely incurable even after intensive multimodal therapy. The lethality of advanced disease is mostly driven by the lack of therapeutic regimens for generating durable responses because of the extreme level of tumor heterogeneity on the genetic and cell biological aspects (10).

NUF2 encodes the *NUF2* protein, a kinetochore protein that forms a stable complex with HEC1, SPC24, and SPC25, named the NDC80 complex. In mitosis, *NUF2*, as well as other components of the NDC80 complex, mainly contribute to kinetochore-microtubule attachment (11). Current evidence has shown that human *NUF2* potentially interacts with centromere-associated protein E and is essential for stable spindle kinetochore-microtubule attachment (12, 13). Evidence showed that down regulation of *NUF2* blocked kinetochore-microtubule attachment and induced mitotic cell death in HeLa cells (11), and the *NUF2* CH domain plays a key role in *NUF2*-mediated kinetochore-microtubule attachment (14). *NUF2* was first identified as an overexpressed protein in various lung cancer histological types through genome-wide expression analysis and named as cell division cycle associated 1 (CDCA1) (15). The activated form of *NUF2* is involved in carcinogenesis and corresponds with patients' prognoses. *NUF2* was reported as a novel cancer-testis antigen that was overexpressed in multiple human cancers including lung, cholangiocellular, renal cell, and

urinary bladder cancers. It was considered as a perfect tumor-associated antigen for both cancer diagnosis and immunotherapy (16). Furthermore, recent findings revealed that knockdown of *NUF2* through siRNA resulted in cell proliferation inhibition and apoptosis induction in different cancer types including colorectal and gastric cancers and osteosarcoma Saos-2 cells (17-19). These reports demonstrate the possible role of *NUF2* in human cancer development.

GMNN, located on chromosome 6, encodes the geminin protein (*GMNN*) (molecular weight, 23565 Da), which is critical for origin licensing. *GMNN* was first identified as a general inhibitor of DNA replication in *Xenopus laevis* egg extracts with no further knowledge of its function in humans (16). Later, *GMNN* was reported as an inhibitor of Cdc10-dependent transcript (Cdt1) (20). A conformational change between *GMNN*-Cdt1 heterotrimer and heterohexamer complex is responsible for licensing or inhibition of DNA replication. *GMNN* inhibits Cdt1-mediated minichromosome maintenance helicases (MCM) loading onto the chromatin-bound origin recognition complex (ORC), which results in the inhibition of pre-replication complex assembly. *GMNN* regulates DNA replication by binding directly to Cdt, affecting its stability and activity, and is involved in different developmental stages through interaction with various proteins (21). Furthermore, *GMNN* expression is highly associated with cancer pathophysiology and development (22).

According to the roles of *NUF2* and *GMNN* in cancer development the goal of this study was to compare the expression levels of these genes in specimens obtained from PC patients at various stages with those from healthy controls to determine whether these genes can be applied as factors to stage PC.

Materials and Methods

Case selection and tissue sampling

Forty PC patients admitted to Shahid Akbar Abadi Hospital (Tehran, Iran) were selected randomly from February to December 2018.

The biopsy test results verified the cancer type; no age limitation was applied during cases selection. Smoking habits and familial history of PC were documented and the PC severity for each patient was measured using the tumor, node, and metastasis (TMN) staging system. The control group consisted of 41 healthy volunteers with no history of malignant or any urological disease.

Sample preparation and RNA extraction

Prostate tissue samples were stored and maintained in liquid nitrogen until RNA extraction. A Super RNA Extraction Kit for Tissue & Culture Cells (Favorgen Biotech Corp, Taiwan) was used to extract the total RNA according to the manufacturer's instructions. The optical density (OD) of each sample at was measured at 260 and 280 nm (Ultrospec 2100 (Biochrom, USA)) and used as criteria to determine the amount of RNA in each sample. RNA was reverse transcribed in 20 µl reaction mixtures containing: first strand buffer, 200 units of Moloney murine leukemia virus reverse transcriptase, 20 units of RNasin, 10 mM DTT, 4.75 µM random hexamers, and 500 µM deoxynucleotides (all from Promega, Madison, WI) at 37 °C for 1 hr. Finally, the resultant mixture was heated at 95 °C for 5 min before storage at -20 °C.

Primers and probes design

The TaqMan primers and probes for the SEC14L1, TCEB1 and FAM72b genes were designed with the help of Primer Express software (PE Applied Biosystems, Foster City, CA). To reduce the DNA contamination, primers were designed to span at least one intron of the respective genomic sequence. To label the TaqMan probes, the dye FAM and the quencher dye TAMRA, with emission wavelengths of 518 and 582 nm, were used at the 5' and 3' ends, respectively. The 3' end of the probe was phosphorylated to prevent extension during PCR. These sequences were checked for their specificity via the Check-Probe function of the Ribosomal Database Project software package and the BLAST database search program. Gene-specific

primers were used according to the following sequences: human *GMNN*, forward primer: 5'-CGGGCGAGCGGAGTTAGCAG-3' and reverse primer: 5'-TGGCTGCAGCACCTCGCAAA-3'; and human *NUF2*, forward primer: 5'-TACCATTAGCAATTTAGTTACT-3' and reverse primer: 5'-TAGAATATCAGCAGTCTCAAAG-3'.

TaqMan real-time PCR

Real-time TaqMan qPCR amplification was performed using a Rotor-Gene 6000 real-time PCR cyler (Qiagen Corbett, Hilden, Germany) with the following method: one step at 95 °C for 5 min, and 40 cycles at 95 °C for 5 sec, and 60 °C for 30 sec. For each step, 20 µl of the reaction mixture was used containing: 0.4 ml of forward primer, 0.4 ml of reverse primer, 0.4 ml of TaqMan probe, 12 µl of Probe 2x Taq (Probe qPCR) Master Mix (Takara Bio, Shiga, Japan), 1 µl of template cDNA, and 5.8 µl of sterilized ultra-pure water. Negative controls included all components of the reaction mixture except for the template cDNA. The negative controls had no detected amplified DNA products and were used during the analysis. The real-time PCRs were performed in triplicate and the data are presented as the mean values of the analysis.

Statistical analysis

In this study subjects' data were obtained through questionnaires and entered into SPSS version 22 (SPSS Inc., Chicago) for analysis. The data are presented as means±SDs. Demographic results were collected from both groups and interpreted according to frequency. Subjects were divided into four age groups as follows: 1) age ≤45, 2) 45 <age ≤54, 3) 54 < age ≤63, and 4) age >63. The Kolmogorov–Smirnov test was used to determine the normal distribution of all data and the Mann-Whitney test was used to evaluate oncogene differences between groups. The chi-square test (X²) was used to determine whether age, smoking, or family history affected PC risk. Eventually, the eta (η) correlation ratio was performed to examine

the relationship between the different oncogenes and the stage of PC. The level of statistical significance was set at $p \leq 0.05$.

Results

Statistics revealed no significant differences in the ages of patients and healthy controls, which ranged from 25 to 88 (48.70 ± 15.32) and 23 to 89 (53.63 ± 13.35) years, respectively. As indicated by the X^2 test, the incidence of PC differed significantly between age groups ($X^2 = 9.30$; $p = 0.026$). The greatest PC prevalence was in

patients ≤ 45 years (16/23) and the least in patients $54 < \text{age} \leq 63$ years (9/28) (Fig. 1). In the control group, no family history of PC was recorded, while among PC patients, 9/37 (24.3%) had family histories of PC (Fig. 2). Regarding smoking, 60 and 51.2% of PC patients and healthy controls smoked, respectively (Fig. 3). Analysis of data by the X^2 test showed that family history of PC significantly affected PC prevalence ($X^2 = 14.43$; $p = 0.001$), while smoking had no significant effect on PC prevalence ($X^2 = 4.67$; $p = 0.097$).




Fig. 1. The number of PC patients and healthy controls in the four age groups.




Fig. 2. The numbers of controls and PC patients without and with family histories of PC; NA: not applicable.




Fig. 3. Percentages of prostate cancer patients and healthy controls who smoked; NA: not applicable.

The patients' PC stages are presented in Table 1. The T2N1M0 stage was the most frequent (47.5 %) among the patients, whereas T1N0M0, T1N1M1, and T4N1M1 were the

least frequent (2.5%). No significant correlation was observed between the PC stage and either smoking habits or family history of PC.

Table 1. The frequency of different TNM staging system of prostate cancer and the corresponding relationship with family history and smoking.

TNM staging system (n= 40)	Frequency (%)	Smoking habit			Family history		
		Yes (%)	No (%)	NA (%)	Yes (%)	No (%)	NA (%)
T1N0M0	1 (2.5)	1 (2.5)	-	-	-	1 (2.5)	-
T1N1M1	1 (2.5)	1 (2.5)	-	-	1 (2.5)	-	-
T2N1M0	19 (47.5)	11 (27.5)	7 (17.5)	1 (2.5)	3 (7.5)	15 (37.5)	1 (2.5)
T2N1M1	4 (10)	-	4 (10)	-	-	4 (10)	-
T2N2M1	7 (17.5)	4 (10)	3 (7.5)	-	2 (5)	4 (10)	1 (2.5)
T3N1M1	2 (5)	-	2 (5)	-	2 (5)	-	-
T4N1M1	1 (2.5)	1 (2.5)	-	-	-	1 (2.5)	-
NA	5 (12.5)	2 (5)	1 (2.5)	2 (5)	1 (2.5)	3 (7.5)	1 (2.5)

T0: In this case, no tumor was found in the prostate tissue

Regarding the importance of *NUF2* and *GMNN* role in malignancies, the mRNA level of these genes from 40 PC patients and 41 healthy controls were measured using qRT-PCR. *NUF2* expression was nearly identical in the two groups; however, *GMNN* expression was significantly greater in PC

tissue samples than in those from the healthy group (2.54±0.290 vs. 1.211±0.117, p< 0.0005) (Fig. 4). Finally, data analysis by eta (η) revealed that the association between the PC stage and *NUF2* and *GMNN* expression was medium and weak, respectively (Table 2).

NUF2 and GMNN Expression in Prostate Cancer




Fig. 4. Relative expression of *NUF2* and *GMNN* in biopsies from cancerous and healthy prostates.

Table 2. Association of *NUF2* and *GMNN* expression level with the stage of PC.

Variable	Value	Interpretation
Stage Dependence	0.883	Medium association between the variables
<i>NUF2</i> Dependence	0.453	
Stage Dependence	1.000	Weak association between the variables
<i>GMNN</i> Dependence	0.356	

Discussion

The current clinical tools for PC progress evaluation, including the pathologic grade and serum prostate-specific (PSA) levels, provide a significant level of discrimination in the identification of those at the highest and lower risk of more aggressive disease (23). For many, this information does not provide a solid picture to determine the most appropriate clinical course (24). Investigating genetic alterations is a new approach to find new targets for tumor therapies, yet few oncogenes have been discovered in prostate carcinogenesis (25, 26). The current study aimed to study two candidate genes suggested to be involved in cancer progression. *NUF2* is reported to stabilize microtubule attachment as part of a linker between the kinetochore and tubulin subunits of the spindle, and depletion of *NUF2* could induce defective kinetochore attachment and spindle checkpoint activation leading to mitotic cells death (27). *NUF2* is a member of cancer/testis (CT) proteins, a group of proteins normally restricted in adult testes of adults but

aberrantly expressed in several types of cancers (28). These antigens are highly immunogenic in cancer patients with an extremely tissue-restricted expression. Prostate cancer is considered a moderate CT gene expressor, with 6/20 (30%) CT transcripts having expression frequencies > 20% (29). In our study, *NUF2* expression was not significantly different between PC patients and controls, in contrast with results of Shiraishi et al., who reported an increase in *NUF2* expression in PC patients following radical prostatectomy (29). Moreover, *NUF2* expression is reported to be altered in a stage-specific manner in prostate carcinogenesis, making it an excellent candidate for cancer staging evaluation (30).

Chromosomal DNA duplication is an essential process for all organisms and needs to be tightly regulated to preserve genomic integrity. *GMNN* is an origin licensing protein with a dual role in the regulation of DNA replication: first, it inhibits replication factor CDT1 activity during the G2 phase of the cell

cycle, and second, it promotes its own accumulation at the G2/M transition. Thereby, *GMNN* prevents DNA re-replication during G2 and ensures that DNA replication is efficiently executed in the next S phase (31). In 2002, *GMNN* was suggested as a marker for cell proliferation in normal tissues and malignancies (32). Furthermore, its ablation resulted in re-replication and DNA damage and enhanced tumorigenesis through increasing genomic instability (33). *GMNN* overexpression was reported in various cancer tissues including PC (34-36). Differential *GMNN* expression is associated with various cancer types, and its expression correlate significantly with nuclear grade and poor prognosis in breast cancer patients (34). Alterations in *GMNN* expression were reported in various cancer tissues (34-36) and findings showed that its overexpression correlated with recruitment and crosstalk with mesenchymal stem cells resulted in enhanced aggressiveness in breast cancer (37), however, Bánfi *et al* (40) found no significant difference in *GMNN* expression in samples from

androgen-sensitive vs androgen-refractory PC samples. In our study, *GMNN* expression was significantly greater in PC patients than in controls. It has been proposed that *GMNN* could be a valuable marker for estimation of tumor aggressiveness and clinical outcome in cancer patients (20, 38, 39). Further studies are required to evaluate *GMNN* as a PC prediction marker and/or therapy target.

Our results revealed that *NUF2* expression was not significantly different, while *GMNN* expression was significantly greater, in PC tissues, which was associated with progression and metastasis in PC patients, than in controls. *GMNN* might be a good candidate for consideration in future studies to find prognostic markers in selection of tumor therapy or the population at risk for cancer progression.

Acknowledgements

We are grateful to Islamic Azad University for general support. The authors declare no conflict of interest.

References

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. *Cancer Epidemiol Biomarkers Prev.* 2016;25(1):16-27.
2. Hosseini M-S, Hosseini F, Ahmadi A, Mozafari M, Amjadi I. Antiproliferative Activity of *Hypericum perforatum*, *Achillea millefolium*, and *Aloe vera* in Interaction with the Prostatic Activity of CD82. *Rep Biochem Mol Biol.* 2019;8(3):260-268.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
4. Kelly SP, Anderson WF, Rosenberg PS, Cook MB. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. *Eur Urol Focus.* 2018;4(1):121-127.
5. Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. *Prostate Int.* 2018;6(2):41-45.
6. Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. *Drugs.* 2019;79(4):381-400.
7. Ha Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men. *Prostate Int.* 2019;7(1):1-8.
8. Vieira-Silva TS, Monteiro-Reis S, Barros-Silva D, Ramalho-Carvalho J, Graça I, Carneiro I, *et al*. Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype. *Cancer Cell Int.* 2019;19:112.
9. Cancer Genome Atlas Research N. The Molecular Taxonomy of Primary Prostate Cancer. *Cell.* 2015;163(4):1011-25.
10. Wang G, Zhao D, Spring DJ, DePinho RA. Genetics and biology of prostate cancer. *Genes Dev.* 2018;32(17-18):1105-40.
11. DeLuca JG, Moree B, Hickey JM, Kilmartin

- JV, Salmon E. hNuf2 inhibition blocks stable kinetochore–microtubule attachment and induces mitotic cell death in HeLa cells. *Cell Biology*. 2002;159(4):549-55.
12. Liu D, Ding X, Du J, Cai X, Huang Y, Ward T, et al. Human *NUF2* interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment. *Journal of Biological Chemistry*. 2007;282(29):21415-24.
13. Brusini L, D'archivio S, McDonald J, Wickstead B. Ndc80/*Nuf2*-like protein KKIP1 connects a stable kinetoplastid outer kinetochore complex to the inner kinetochore and responds to metaphase tension. *BioRxiv*. 2019:764829.
14. Sundin LJ, Guimaraes GJ, DeLuca JG. The NDC80 complex proteins *Nuf2* and *Hec1* make distinct contributions to kinetochore–microtubule attachment in mitosis. *Molecular Biology of The Cell*. 2011;22(6):759-68.
15. Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. *Cancer Research*. 2006;66(21):10339-48.
16. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. *International Journal of Cancer*. 2008;123(11):2616-25.
17. Kaneko N, Miura K, Gu Z, Karasawa H, Ohnuma S, Sasaki H, et al. siRNA-mediated knockdown against CDCA1 and KNTC2, both frequently overexpressed in colorectal and gastric cancers, suppresses cell proliferation and induces apoptosis. *Biochemical and Biophysical Research Communications*. 2009;390(4):1235-40.
18. Fu H, Shao L. Silencing of *NUF2* inhibits proliferation of human osteosarcoma Saos-2 cells. *European Review for Medical and Pharmacological Sciences*. 2016;20(6):1071-9.
19. Hu P, Shanguan J, Zhang L. Downregulation of *NUF2* inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813. *International Journal of Clinical and Experimental Pathology*. 2015;8(3):2638.
20. Haruki T, Shomori K, Hamamoto Y, Taniguchi Y, Nakamura H, Ito H. Geminin expression in small lung adenocarcinomas: implication of prognostic significance. *Lung Cancer*. 2011;71(3):356-62.
21. Fame RM, Lehtinen MK. Sister, Sister: Ependymal Cells and Adult Neural Stem Cells Are Separated at Birth by Geminin Family Members. *Neuron*. 2019;102(2):278-9.
22. Zhang L, Cai M, Gong Z, Zhang B, Li Y, Guan L, et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis. *The Journal of Clinical Investigation*. 2017;127(6):2159-75.
23. Carter HB. Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. *Asian Journal of Andrology*. 2012;14(3):355.
24. Nguyen CT, Kattan MW. Formalized prediction of clinically significant prostate cancer: is it possible? *Asian Journal of Andrology*. 2012;14(3):349.
25. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. *Genes Dev*. 2010;24(18):1967-2000.
26. Dong JT. Prevalent mutations in prostate cancer. *Journal of cellular biochemistry*. 2006;97(3):433-47.
27. Liu Q, Dai S-J, Li H, Dong L, Peng Y-P. Silencing of *NUF2* inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. *Asian Pac J Cancer Prev*. 2014;15(20):8623-9.
28. Scanlan MJ, Simpson A, Old LJ. The cancer/testis genes: review, standardization, and commentary. *Cancer Immune*. 2004;4.
29. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, et al. Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. *J Transl Med*. 2011;9:153.
30. Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg RH. Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer. *Urology*. 2015;85(3):704.e1-7.
31. Ballabeni A, Zamponi R, Moore JK, Helin K, Kirschner MW. Geminin deploys multiple mechanisms to regulate Cdt1 before cell division

thus ensuring the proper execution of DNA replication. *Proc Natl Acad Sci U S A*. 2013;110(30):E2848-53.

32. Wohlschlegel JA, Kutok JL, Weng AP, Dutta A. Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. *Am J Pathol*. 2002;161(1):267-73.

33. Champeris Tsaniras S, Villiou M, Giannou AD, Nikou S, Petropoulos M, Pateras IS, et al. Geminin ablation *in vivo* enhances tumorigenesis through increased genomic instability. *J Pathol*. 2018;246(2):134-140.

34. Yagi T, Inoue N, Yanai A, Murase K, Imamura M, Miyagawa Y, et al. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. *Breast Cancer*. 2016;23(2):224-30.

35. Xing Y, Wang C, Wu J. Expression of geminin, p16, and Ki67 in cervical intraepithelial neoplasm and normal tissues. *Medicine (Baltimore)*. 2017;96(26):e7302.

36. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary

gland tumours. *J Oral Pathol Med*. 2008;37(5):309-18.

37. Ananthula S, Sinha A, El Gassim M, Batth S, Marshall Jr GD, Gardner LH, et al. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers. *Oncotarget*. 2016;7(15):20869-89.

38. Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, et al. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. *Gastric Cancer*. 2010;13(3):177-85.

39. Di Bonito M, Cantile M, Collina F, Scognamiglio G, Cerrone M, La Mantia E, et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. *J Breast Cancer*. 2012;15(2):162-71.

40. Bánfi G, Teleki I, Nyirády P, Keszthelyi A, Romics I, Fintha A, et al. Changes of protein expression in prostate cancer having lost its androgen sensitivity. *International Urology and Nephrology*. 2015;47(7):1149-54.